Medpace Holdings, Inc. (NASDAQ: MEDP) Stock Competitors & Peer Comparison
See MEDP's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MEDP and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDP | $602.90 | -2.84% | 16.8B | 35.34 | $17.06 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $656.58 | -2.98% | 242.8B | 28.35 | $23.16 | +0.28% |
| DHR | $215.61 | -2.53% | 151.5B | 27.01 | $7.98 | +0.70% |
| NTRA | $400.65 | -5.87% | 57.4B | -303.52 | -$1.32 | N/A |
| A | $169.33 | -1.14% | 47.8B | 29.15 | $5.81 | +0.60% |
| WAT | $436.43 | -0.84% | 42.9B | 31.90 | $13.68 | N/A |
| IQV | $259.98 | -2.30% | 42.8B | 21.45 | $12.13 | N/A |
| ILMN | $273.54 | -6.86% | 41.4B | 54.38 | $5.03 | N/A |
| IDXX | $515.41 | -2.21% | 40.7B | 36.25 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
MEDP vs DHR-PB Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, MEDP's ROE is +1.10%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
MEDP vs TMO Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, TMO has a market cap of 242.8B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while TMO trades at $656.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas TMO's P/E ratio is 28.35. In terms of profitability, MEDP's ROE is +1.10%, compared to TMO's ROE of +0.13%. Regarding short-term risk, MEDP is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
MEDP vs DHR Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, DHR has a market cap of 151.5B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while DHR trades at $215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas DHR's P/E ratio is 27.01. In terms of profitability, MEDP's ROE is +1.10%, compared to DHR's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
MEDP vs NTRA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NTRA has a market cap of 57.4B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NTRA trades at $400.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NTRA's P/E ratio is -303.52. In terms of profitability, MEDP's ROE is +1.10%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, MEDP is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
MEDP vs A Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, A has a market cap of 47.8B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while A trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas A's P/E ratio is 29.15. In terms of profitability, MEDP's ROE is +1.10%, compared to A's ROE of +0.20%. Regarding short-term risk, MEDP is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check A's competition here
Waters Corporation (NYSE: WAT)
MEDP vs WAT Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, WAT has a market cap of 42.9B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while WAT trades at $436.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas WAT's P/E ratio is 31.90. In terms of profitability, MEDP's ROE is +1.10%, compared to WAT's ROE of +0.02%. Regarding short-term risk, MEDP is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
MEDP vs IQV Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while IQV trades at $259.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas IQV's P/E ratio is 21.45. In terms of profitability, MEDP's ROE is +1.10%, compared to IQV's ROE of +0.22%. Regarding short-term risk, MEDP is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
MEDP vs ILMN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ILMN has a market cap of 41.4B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ILMN trades at $273.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ILMN's P/E ratio is 54.38. In terms of profitability, MEDP's ROE is +1.10%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, MEDP is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
MEDP vs IDXX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, IDXX has a market cap of 40.7B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while IDXX trades at $515.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas IDXX's P/E ratio is 36.25. In terms of profitability, MEDP's ROE is +1.10%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, MEDP is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
MEDP vs MTD Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, MTD has a market cap of 31B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while MTD trades at $1,533.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas MTD's P/E ratio is 35.21. In terms of profitability, MEDP's ROE is +1.10%, compared to MTD's ROE of -12.00%. Regarding short-term risk, MEDP is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
MEDP vs LH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while LH trades at $311.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas LH's P/E ratio is 18.50. In terms of profitability, MEDP's ROE is +1.10%, compared to LH's ROE of +0.12%. Regarding short-term risk, MEDP is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
MEDP vs DGX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, DGX has a market cap of 25.2B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while DGX trades at $228.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas DGX's P/E ratio is 22.53. In terms of profitability, MEDP's ROE is +1.10%, compared to DGX's ROE of +0.14%. Regarding short-term risk, MEDP is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
MEDP vs GH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas GH's P/E ratio is -48.91. In terms of profitability, MEDP's ROE is +1.10%, compared to GH's ROE of +2.11%. Regarding short-term risk, MEDP is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
MEDP vs EXAS Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas EXAS's P/E ratio is -95.37. In terms of profitability, MEDP's ROE is +1.10%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, MEDP is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check EXAS's competition here
Revvity, Inc. (NYSE: RVTY)
MEDP vs RVTY Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, RVTY has a market cap of 17.1B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while RVTY trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas RVTY's P/E ratio is 28.66. In terms of profitability, MEDP's ROE is +1.10%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, MEDP is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
MEDP vs ILMNV Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ILMNV's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to ILMNV's ROE of N/A. Regarding short-term risk, MEDP is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
MEDP vs CRL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CRL has a market cap of 14.7B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CRL trades at $304.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CRL's P/E ratio is 30.81. In terms of profitability, MEDP's ROE is +1.10%, compared to CRL's ROE of -0.08%. Regarding short-term risk, MEDP is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
MEDP vs PKI Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas PKI's P/E ratio is 41.45. In terms of profitability, MEDP's ROE is +1.10%, compared to PKI's ROE of +0.03%. Regarding short-term risk, MEDP is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
MEDP vs ICLR Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ICLR trades at $161.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ICLR's P/E ratio is 13.19. In terms of profitability, MEDP's ROE is +1.10%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, MEDP is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
MEDP vs QGEN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, QGEN has a market cap of 9.4B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while QGEN trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas QGEN's P/E ratio is 18.87. In terms of profitability, MEDP's ROE is +1.10%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, MEDP is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
MEDP vs GRAL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while GRAL trades at $137.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas GRAL's P/E ratio is -14.08. In terms of profitability, MEDP's ROE is +1.10%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, MEDP is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
MEDP vs RDNT Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while RDNT trades at $70.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas RDNT's P/E ratio is 152.78. In terms of profitability, MEDP's ROE is +1.10%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, MEDP is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
MEDP vs SHC Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while SHC trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas SHC's P/E ratio is 19.01. In terms of profitability, MEDP's ROE is +1.10%, compared to SHC's ROE of +0.27%. Regarding short-term risk, MEDP is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
MEDP vs BLLN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BLLN trades at $99.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BLLN's P/E ratio is 142.72. In terms of profitability, MEDP's ROE is +1.10%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, MEDP is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
MEDP vs SYNH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas SYNH's P/E ratio is 61.40. In terms of profitability, MEDP's ROE is +1.10%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
MEDP vs VCYT Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while VCYT trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas VCYT's P/E ratio is 22.33. In terms of profitability, MEDP's ROE is +1.10%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, MEDP is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
MEDP vs CDNA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CDNA trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CDNA's P/E ratio is 75.94. In terms of profitability, MEDP's ROE is +1.10%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, MEDP is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
MEDP vs OLK Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas OLK's P/E ratio is -96.59. In terms of profitability, MEDP's ROE is +1.10%, compared to OLK's ROE of -0.07%. Regarding short-term risk, MEDP is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
MEDP vs WGS Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while WGS trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas WGS's P/E ratio is 198.67. In terms of profitability, MEDP's ROE is +1.10%, compared to WGS's ROE of -0.39%. Regarding short-term risk, MEDP is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
MEDP vs PSNL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while PSNL trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas PSNL's P/E ratio is -14.71. In terms of profitability, MEDP's ROE is +1.10%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, MEDP is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
MEDP vs OPK Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while OPK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas OPK's P/E ratio is -16.22. In terms of profitability, MEDP's ROE is +1.10%, compared to OPK's ROE of -0.06%. Regarding short-term risk, MEDP is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
MEDP vs CSTL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CSTL trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CSTL's P/E ratio is -50.55. In terms of profitability, MEDP's ROE is +1.10%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, MEDP is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
MEDP vs FLGT Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, FLGT has a market cap of 584.5M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while FLGT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas FLGT's P/E ratio is 2058.00. In terms of profitability, MEDP's ROE is +1.10%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, MEDP is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
MEDP vs GRALV Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas GRALV's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to GRALV's ROE of N/A. Regarding short-term risk, MEDP is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
MEDP vs NEO Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NEO has a market cap of 424.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NEO trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NEO's P/E ratio is 126.96. In terms of profitability, MEDP's ROE is +1.10%, compared to NEO's ROE of -0.06%. Regarding short-term risk, MEDP is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
MEDP vs MYGN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas MYGN's P/E ratio is -32.92. In terms of profitability, MEDP's ROE is +1.10%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, MEDP is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
MEDP vs CO Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CO's P/E ratio is 5.06. In terms of profitability, MEDP's ROE is +1.10%, compared to CO's ROE of +0.11%. Regarding short-term risk, MEDP is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
MEDP vs FLDM Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas FLDM's P/E ratio is -4.74. In terms of profitability, MEDP's ROE is +1.10%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, MEDP is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
MEDP vs BDSX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BDSX has a market cap of 227.6M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BDSX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BDSX's P/E ratio is -8.82. In terms of profitability, MEDP's ROE is +1.10%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, MEDP is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
MEDP vs XGN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, XGN has a market cap of 197.9M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while XGN trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas XGN's P/E ratio is -10.11. In terms of profitability, MEDP's ROE is +1.10%, compared to XGN's ROE of -1.22%. Regarding short-term risk, MEDP is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
MEDP vs FRNM Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, FRNM has a market cap of 133.5M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while FRNM trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas FRNM's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to FRNM's ROE of N/A. Regarding short-term risk, MEDP is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
MEDP vs GTH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas GTH's P/E ratio is -1.11. In terms of profitability, MEDP's ROE is +1.10%, compared to GTH's ROE of -1.01%. Regarding short-term risk, MEDP is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
MEDP vs GENE Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas GENE's P/E ratio is -38.25. In terms of profitability, MEDP's ROE is +1.10%, compared to GENE's ROE of -1.85%. Regarding short-term risk, MEDP is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
MEDP vs IMDX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas IMDX's P/E ratio is -2.27. In terms of profitability, MEDP's ROE is +1.10%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, MEDP is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
MEDP vs SERA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas SERA's P/E ratio is -3.15. In terms of profitability, MEDP's ROE is +1.10%, compared to SERA's ROE of -0.47%. Regarding short-term risk, MEDP is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
MEDP vs PRPO Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, PRPO has a market cap of 41.8M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while PRPO trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas PRPO's P/E ratio is -36.08. In terms of profitability, MEDP's ROE is +1.10%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, MEDP is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
MEDP vs MDXH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, MDXH has a market cap of 30.8M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas MDXH's P/E ratio is -0.82. In terms of profitability, MEDP's ROE is +1.10%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, MEDP is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
MEDP vs QUCY Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas QUCY's P/E ratio is -0.06. In terms of profitability, MEDP's ROE is +1.10%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, MEDP is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
MEDP vs AKU Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas AKU's P/E ratio is -0.13. In terms of profitability, MEDP's ROE is +1.10%, compared to AKU's ROE of -5.32%. Regarding short-term risk, MEDP is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
MEDP vs BNR Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BNR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BNR's P/E ratio is -18.97. In terms of profitability, MEDP's ROE is +1.10%, compared to BNR's ROE of -0.13%. Regarding short-term risk, MEDP is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
MEDP vs CEMI Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CEMI's P/E ratio is -0.63. In terms of profitability, MEDP's ROE is +1.10%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, MEDP is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
MEDP vs ENZ Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ENZ's P/E ratio is -2.24. In terms of profitability, MEDP's ROE is +1.10%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, MEDP is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
MEDP vs PMD Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas PMD's P/E ratio is -5.24. In terms of profitability, MEDP's ROE is +1.10%, compared to PMD's ROE of -0.32%. Regarding short-term risk, MEDP is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
MEDP vs ME Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ME's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.10%, compared to ME's ROE of -3.47%. Regarding short-term risk, MEDP is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
MEDP vs MYNZ Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, MEDP's ROE is +1.10%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, MEDP is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
MEDP vs BIAFW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BIAFW has a market cap of 12.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BIAFW trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BIAFW's P/E ratio is 1.29. In terms of profitability, MEDP's ROE is +1.10%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, MEDP is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
MEDP vs CHEK Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CHEK's P/E ratio is -0.43. In terms of profitability, MEDP's ROE is +1.10%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, MEDP is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
MEDP vs CNTG Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CNTG's P/E ratio is -0.23. In terms of profitability, MEDP's ROE is +1.10%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, MEDP is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
MEDP vs ADVB Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ADVB's P/E ratio is -58.00. In terms of profitability, MEDP's ROE is +1.10%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, MEDP is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
MEDP vs NDRA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NDRA's P/E ratio is -0.90. In terms of profitability, MEDP's ROE is +1.10%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, MEDP is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
MEDP vs APDN Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas APDN's P/E ratio is -0.10. In terms of profitability, MEDP's ROE is +1.10%, compared to APDN's ROE of -7.23%. Regarding short-term risk, MEDP is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
MEDP vs NVTA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NVTA's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.10%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, MEDP is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
MEDP vs LMDXW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.10%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, MEDP is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
MEDP vs LMDX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas LMDX's P/E ratio is -0.01. In terms of profitability, MEDP's ROE is +1.10%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, MEDP is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
MEDP vs DMTK Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas DMTK's P/E ratio is -0.04. In terms of profitability, MEDP's ROE is +1.10%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, MEDP is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
MEDP vs NOTV Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NOTV's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.10%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, MEDP is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
MEDP vs ISPC Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas ISPC's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.10%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, MEDP is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
MEDP vs BIAF Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BIAF's P/E ratio is -0.71. In terms of profitability, MEDP's ROE is +1.10%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, MEDP is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
MEDP vs SQL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas SQL's P/E ratio is -0.40. In terms of profitability, MEDP's ROE is +1.10%, compared to SQL's ROE of -30.46%. Regarding short-term risk, MEDP is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
MEDP vs AWH Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas AWH's P/E ratio is -0.09. In terms of profitability, MEDP's ROE is +1.10%, compared to AWH's ROE of +1.62%. Regarding short-term risk, MEDP is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
MEDP vs HTGM Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas HTGM's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.10%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, MEDP is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
MEDP vs BIOC Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BIOC's P/E ratio is -0.01. In terms of profitability, MEDP's ROE is +1.10%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, MEDP is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
MEDP vs SQLLW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.10%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, MEDP is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
MEDP vs WGSWW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.10%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, MEDP is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
MEDP vs DHR-PA Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, MEDP's ROE is +1.10%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
MEDP vs PRXL Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas PRXL's P/E ratio is 42.97. In terms of profitability, MEDP's ROE is +1.10%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, MEDP is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
MEDP vs MEUSW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas MEUSW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, MEDP is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
MEDP vs NDRAW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas NDRAW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, MEDP is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
MEDP vs CHEKZ Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, MEDP is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
MEDP vs OCDX Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas OCDX's P/E ratio is -42.28. In terms of profitability, MEDP's ROE is +1.10%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, MEDP is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for MEDP.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
MEDP vs BNGOW Comparison October 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 16.8B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, MEDP is priced at $602.90 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 35.34, whereas BNGOW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.10%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, MEDP is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for MEDP.Check BNGOW's competition here